52 results
8-K
EX-10.2
SYRS
Syros Pharmaceuticals Inc.
13 Oct 21
Departure of Directors or Certain Officers
4:01pm
and the Company, the right to exercise this option shall terminate immediately upon such violation.
(d) Exercise Period Upon Death or Disability … the period of one year following the date of death or disability of the Participant, by the Participant (or in the case of death by an authorized
8-K
EX-10.3
SYRS
Syros Pharmaceuticals Inc.
5 Jul 22
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
7:07am
of the undersigned’s Family Members, (B) to the undersigned’s estate, following the death of the undersigned, by will, intestacy or other operation of Law
8-K
EX-99.2
jwzst2
15 Sep 22
Departure of Directors or Certain Officers
4:06pm
8-K
EX-99.1
wjx7c3kefr6p1s
15 Nov 18
Regulation FD Disclosure
4:03pm
8-K
EX-99.1
1zsc4ua
6 Dec 23
Regulation FD Disclosure
7:05am
425
f5y evgh2a
15 Sep 22
Business combination disclosure
4:08pm
8-K
EX-99.1
jrwuw2
5 Jul 22
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
7:07am
S-4
EX-10.5
z5uxqs8gc pgynrj
18 Jul 22
Registration of securities issued in business combination transactions
7:58am
8-K
EX-99.1
ymc4naoa2r6u0om4u
15 Sep 22
Departure of Directors or Certain Officers
4:06pm
8-K
EX-10.1
ktcym5
13 Oct 21
Departure of Directors or Certain Officers
4:01pm
8-K
EX-1.1
a4d2 45n4a
20 Jan 21
Syros Announces Proposed Offering of Common Stock
4:04pm